Positioned in the goldilocks spot between small molecules and biologics, peptide therapeutics have undergone an exciting uphill trajectory within the last decade. Fuelled by advances in synthesis and screening technologies, together with novel design and delivery strategies to surmount their inherent drawbacks, this modality is showing new levels of promise. The momentum behind this exciting modality is evidenced in the billion-dollar deals from industry giants such as Genentech and Merck, signalling a surge in interest from an expanding array of companies venturing into the field of next-generation peptide-based drugs.

The first industry-focused event dedicated towards this exciting new modality, the Peptide Based Therapeutics Summit united pioneers from Johnson & Johnson, Fog Pharma, Genentech & PeptiDream, spanning diverse diseases and therapeutic approaches. Whether you're focused on peptide-drug conjugates, bicyclic or macro-cyclic peptides, PCSK9, GLP, or any other peptide based therapeutic, this offered an invaluable opportunity to learn from peers, accelerate discovery and de-risk the development of your peptide therapeutics.

As we enter the third wave of peptide-based therapeutics, this therapeutic and disease agnostic meeting brought together the leading minds in early discovery, pre-formulation, heads of peptide drug development and pioneering peptide chemists. In 2024, we dissected challenges related to improving peptide stability, raising oral bioavailability and balancing cell permeability with intracellular target selectivity, as well as explored how the latest cutting-edge technology can help you arrive at the optimal lead compound. Our audience joined us to help shape the trajectory of these remarkable drugs across various therapeutic landscapes.